Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Treating the treatments

Lessons from ASCO

Treating the treatments

While targeted therapies were hot topics at this year's American Society of Clinical Oncology meeting, systemic cancer therapies aren't going to be usurped from their entrenched positions in treatment regimens in the foreseeable future. Thus, companies see large opportunities to develop treatments for the side effects of chemotherapy and radiation therapy, which include chemotherapy-induced nausea and vomiting (CINV) and oral mucositis.

In CINV, incremental improvements in existing treatments may be enough to garner market share, while mucositis is an underserved indication

Read the full 859 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE